Skip to main content

Table 4 Central nervous system metastases progression rate

From: Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population

  (N = 248) (N = 203)  
CNS as new sites of progression 11 6  
Progression of CNS metastases at baseline 20 6  
CNS progression rate 12.5% 5.9% 0.018